At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.
Among the reasons documented for some patients discontinuing biosimilar infliximab after switching from the reference product are subjective loss of response and adverse events.
At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.
In the retrospective, observation, multicenter cohort study, data from patients with IBD who had switched to CT-P13 and had at least 52 weeks of follow-up were eligible for inclusion. In total, 254 patients were switched, 165 of whom had Crohn disease (CD), 52 of whom had ulcerative colitis (UC), and 2 of whom had unclassified IBD.
In total, 35 patients switched back to the originator drug during the follow-up period. Those who made the switch back were more often female than those who remained on the biosimilar. In total, 91.4% of those who switched back did so because of newly reported side effects. Only 3 (8.6%) switched back due to loss of response.
The side effects most commonly reported were skin reactions (37.1%), increased IBD-related symptoms (37.1%), and fatigue (25.7%). Three patients had calprotectin-objectified loss of response.
In 75% of the patients who reported new side effects and in 100% of the patients with loss of response, switching back to the reference product had the desired effect of improving the side effects or regaining response.
The authors concluded that, for those who experience side effects or a loss of response after a switch to the biosimilar product, a switch back may be justified, and appears to have been effective in this group of patients with IBD.
Reference
Mahmmod S, Schultheiss JPD, Mahmmod N, Tan AC, Dijkstra G, Fidder HH. Reverse switching to originator infliximab may be considered in patients with inflammatory bowel diseases experiencing new side effects or loss of response after switching to a CT-P13 biosimilar. Presented at: United European Gastroenterology Week 2019; October 29-23, 2019; Barcelona, Spain.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).